PMID- 33279908
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20231213
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 99
IP  - 4
DP  - 2021
TI  - The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese 
      Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A 
      Real-World Study.
PG  - 203-214
LID - 10.1159/000511734 [doi]
AB  - AIM: The aim of this retrospective study was to investigate the efficacy and 
      safety of ramucirumab treatment under real-world conditions and to clarify the 
      role of albumin-bilirubin (ALBI) score in predicting outcomes. METHODS: Between 
      June 2019 and May 2020, a total of 16 patients with advanced hepatocellular 
      carcinoma (HCC) treated with ramucirumab in Gunma Saiseikai Maebashi Hospital and 
      its affiliated hospitals was included. RESULTS: The median age was 71 
      (interquartile range [IQR] 65-74) years old, and 12 patients (75.0%) were male. 
      The modified ALBI (mALBI) grade was 1, 2a, and 2b at baseline in 4 (25.0%), 3 
      (18.8%), and 9 patients (56.3%), respectively. The Barcelona Clinic Liver Cancer 
      stage was intermediate and advanced stage in 1 (6.3%) and 15 patients (93.8%), 
      respectively. The serum alpha-fetoprotein at baseline was 4,911 (IQR 2,091-17,377) 
      ng/mL. The disease control rate in patients with mALBI grade1 + 2a was 
      significantly higher than in those with mALBI grade 2b (100 vs. 28.6%, p = 
      0.028). The patients with mALBI grade 1 + 2a had a significantly better overall 
      survival (OS) and longer progression-free survival (PFS) than those with mALBI 
      grade 2b (median OS 6.7 vs. 3.0 months; p = 0.036, median PFS 7.5 vs. 1.4 months; 
      p = 0.002). The number of cycles of ramucirumab treatment was significantly 
      correlated with the ALBI score (r = -0.452, p = 0.030). The patients with mALBI 
      grade 1 + 2a showed a low incidence of adverse events (AEs) and discontinuation 
      due to AEs. CONCLUSIONS: Advanced HCC patients with mALBI grade 1 + 2a may be a 
      good indication for ramucirumab treatment.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Hatanaka, Takeshi
AU  - Hatanaka T
AD  - Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, 
      Japan, hatanaka@qk9.so-net.ne.jp.
FAU - Naganuma, Atsushi
AU  - Naganuma A
AD  - Department of Gastroenterology, National Hospital Organization Takasaki General 
      Medical Center, Takasaki, Japan.
FAU - Shibasaki, Mitsuhiko
AU  - Shibasaki M
AD  - Department of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Japan.
FAU - Kohga, Tatsuya
AU  - Kohga T
AD  - Department of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Japan.
FAU - Arai, Yosuke
AU  - Arai Y
AD  - Department of Internal Medicine, Kiryu Kosei General Hospital, Kiryu, Japan.
FAU - Nagashima, Tamon
AU  - Nagashima T
AD  - Department of Gastroenterology, National Hospital Organization Shibukawa Medical 
      Center, Shibukawa, Japan.
FAU - Ueno, Takashi
AU  - Ueno T
AD  - Department of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Japan.
FAU - Namikawa, Masashi
AU  - Namikawa M
AD  - Department of Internal Medicine, Kiryu Kosei General Hospital, Kiryu, Japan.
FAU - Saito, Shuichi
AU  - Saito S
AD  - Department of Gastroenterology, Tomioka General Hospital, Tomioka, Japan.
FAU - Hoshino, Takashi
AU  - Hoshino T
AD  - Department of Gastroenterology, National Hospital Organization Takasaki General 
      Medical Center, Takasaki, Japan.
FAU - Takizawa, Daichi
AU  - Takizawa D
AD  - Department of Gastroenterology, Maebashi Red Cross Hospital, Maebashi, Japan.
FAU - Arai, Hirotaka
AU  - Arai H
AD  - Department of Gastroenterology, Maebashi Red Cross Hospital, Maebashi, Japan.
FAU - Makita, Fujio
AU  - Makita F
AD  - Department of Gastrointestinal Surgery, National Hospital Organization Shibukawa 
      Medical Center, Shibukawa, Japan.
FAU - Kakizaki, Satoru
AU  - Kakizaki S
AD  - Department of Gastroenterology and Hepatology, Gunma University Graduate School 
      of Medicine​, Maebashi, Japan.
AD  - Department of Clinical Research, National Hospital Organization Takasaki General 
      Medical Center, Takasaki, Japan.
FAU - Harimoto, Norifumi
AU  - Harimoto N
AD  - Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate 
      School of Medicine​, Maebashi, Japan.
FAU - Shirabe, Ken
AU  - Shirabe K
AD  - Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate 
      School of Medicine​, Maebashi, Japan.
FAU - Uraoka, Toshio
AU  - Uraoka T
AD  - Department of Gastroenterology and Hepatology, Gunma University Graduate School 
      of Medicine​, Maebashi, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (AFP protein, human)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (alpha-Fetoproteins)
RN  - RFM9X3LJ49 (Bilirubin)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - Bilirubin/*blood
MH  - Carcinoma, Hepatocellular/blood/*drug therapy/epidemiology/pathology
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Liver Function Tests
MH  - Liver Neoplasms/blood/*drug therapy/epidemiology/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Serum Albumin, Human/*analysis
MH  - alpha-Fetoproteins/analysis
MH  - Ramucirumab
OTO - NOTNLM
OT  - Albumin-bilirubin grade
OT  - Hepatocellular carcinoma
OT  - Modified albumin-bilirubin grade
OT  - Ramucirumab
OT  - alpha-Fetoprotein
EDAT- 2020/12/07 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/12/06 20:49
PHST- 2020/09/12 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/12/07 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/12/06 20:49 [entrez]
AID - 000511734 [pii]
AID - 10.1159/000511734 [doi]
PST - ppublish
SO  - Oncology. 2021;99(4):203-214. doi: 10.1159/000511734. Epub 2020 Dec 4.